Blocking integrin inactivation as an anti‐angiogenic therapy |
| |
| Authors: | Pipsa Saharinen Johanna Ivaska |
| |
| Affiliation: | 1. Wihuri Research Institute and Research Programs Unit, Translational Cancer Biology Program and Department of Virology, University of Helsinki, Helsinki, Finland;2. Department of Food and Biochemistry, Turku Centre for Biotechnology, University of Turku, Turku, Finland |
| |
| Abstract: | During angiogenesis, endothelial cell migration is coordinated by integrin‐mediated contact with the extra‐cellular matrix (ECM), coupled with receptor tyrosine kinase signalling to regulate dynamic cytoskeletal and plasma membrane reorganization. A recent paper by Vitorino et al ( 2015 ) defined a new MAP4K4–moesin–talin–β1‐integrin pathway that could be therapeutically exploited to suppress pathologic angiogenesis. |
| |
| Keywords: | |
|
|
